Table 4.

Adjusted hazard ratios (HR) from a multivariable analysis based on Cox models including age category, gender, PS, cell of origin, respiratory comorbidity, diabetes, other malignancies, and first-line treatments.

Variable	Category	Hazard ratio	95% Confidence interval	p value
Age category	60–69 years	1.81	1.40–2.35	<0.0001
(Ref: 20–59 years)	70–79 years	2.62	2.05–3.34	<0.0001
	80–84 years	4.13	3.18–5.35	<0.0001
	85+ years	5.95	4.53–7.82	<0.0001
Gender	Male	1.25	1.10–1.42	0.0008
Performance status early a	>1	4.56	3.43–6.06	<0.0001
Performance status late a	>1	1.88	1.53–2.30	<0.0001
BCL2 overexpression b	Yes	1.51	1.08–2.12	0.0159
Cell of origin b	Non-GCB	1.45	1.14–1.84	0.0022
Comorbidity c	Respiratory	1.41	1.15–1.73	0.0009
	Diabetes	1.24	1.05–1.46	0.0119
Other malignancies d	Before	1.34	1.07–1.68	0.0117
	After	2.50	1.96–3.20	<0.0001
First-line treatment e	Full R-CHOP f	0.41	0.33–0.52	<0.0001
	Other anthracycline	0.72	0.55–0.94	0.0143

Only those with a significant HR are shown, results on all evaluated variables can be found in Supplementary Table 9 .

^aImpact on OS during time period ≤0.25 (early) versus >0.25 (late) years from incidence.

^bImpact on OS during time period >1 year from incidence. Not significant at ≤1 year.

^cBased on reimbursed drugs in same time period.

^dOther malignancies before or after the diagnosis of DLBCL.

^eEach treatment has been included in the model as time dependent variable to overcome immortal time bias.

^fR-(mini)CHOP for ≥ 6 cycles (≥ 4 if Ann Arbor stage = I).

non-GCB, non germinal center B-cell; OS, overall survival; BCL2, B-cell lymphoma 2; DLBCL, diffuse large B-cell lymphoma; PS, performance status; R-(mini)CHOP, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone; Ref, reference.